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1. Resymé (Summary in Norwegian) 
Glaukom er en kronisk nevrodegenerativ sykdom som rammer nervus opticus, og er en av de 
vanligste årsakene til synstap i verden. Primært åpenvinklet glaukom (POAG) og 
eksfoliasjonsglaukom (XFG) er de hyppigst forekommende glaukomtyper i Norge. 
Eksfoliasjonsmateriale hos pasienter med XFG/eksfoliasjonssyndrom (XFS) har vært funnet 
på flere lokalisasjoner utenfor øyet, og dette ledet fram til hypotesene om at XFS kan være et 
ledd i en systemsykdom og at dødeligheten i denne pasientgruppen kunne være høyere. Flere 
tidligere studier har konkludert med at glaukompasienter har høyere mortalitet enn 
gjennomsnittsbefolkningen. Vi undersøkte retrospektivt om det var forskjeller mellom POAG 
og XFG med hensyn til overlevelse, dødsårsaker og assosiasjoner med andre sykdommer hos 
1147 pasienter innlagt for glaukom mellom 1961 og 1970. Det ble ikke observert forskjeller 
mellom de to diagnosegruppene når det gjaldt overlevelse. Akutt cerebrovaskulær sykdom og 
kronisk cerebral sykdom som senil demens, cerebral atrofi og kronisk cerebral iskemi, var 
hyppigere assosiert med XFG enn POAG. Bruk av acetazolamid peroralt medførte økt risiko 
for kroniske cerebrale sykdommer og redusert overlevelse. Både OAG og XFG forekommer 
hyppigere hos pasienter med Alzheimers sykdom (AD). Vi undersøkte om subgrupper av 
APOE- og CHRNA4-genotypen som har vært assosiert med AD, hadde påvirkning på 
nervefiberlagstykkelse på papillen, intraokulært trykk (IOP), forekomst av 
eksfoliasjonssyndrom (XFS), katarakt og aldersrelatert makuladegenerasjon (AMD) hos 88 
friske deltakere. Vi fant ingen sammenheng mellom APOE- og CHRNA4-genotyper og 
nervefiberlagtykkelse på papillen. IOP var lavere hos APOE2-bærerne enn hos ikke-APOE2-
bærerne. XFS var mindre hyppig hos CC-bærerne av CHRNA4-genotypen enn hos TT- og 
TC-bærerne. Vi fant ingen sammenheng mellom APOE-genotype og forekomst av AMD. 
APOE3-bærerne hadde tykkere makula og bedre visus enn ikke-APOE3-bærerne. APOE4-
bærerne hadde lavere risiko for å utvikle katarakt enn ikke-APOE4-bærerne.   
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4. Introduction 
Glaucoma is one of the leading causes of vision loss in the world, particularly among the 
elderly (Leske 1983; Quigley 1996). The disease is characterized by retinal ganglion cell 
death, axon loss, and an excavated appearance to the optic nerve head, and progressive visual 
field loss (Quigley & Green 1979). Although elevation of intraocular pressure (IOP) is 
recognized as a major risk factor for optic damage in glaucoma (Anderson 1989), multiple 
factors other than IOP, including genetic factors (Friedman & Walter 1999), are likely to have 
a role in the pathogenesis of glaucomatous optic neuropathy. 
 
Survival 
Primary open-angle glaucoma (POAG) and exfoliative glaucoma (XFG) are the most frequent 
types of glaucoma in the Norwegian population (Ringvold et al. 1991). Previous studies have 
shown reduced survival rates for patients with open-angle glaucoma (Belloc 1963; Thorburn 
& Lindholm 1983; Hiller et al. 1999; Lee et al. 2003). XFG and exfoliation syndrome (XFS) 
were earlier considered to be a condition of purely ophthalmological interest. However, 
similar deposits of exfoliation material have been found in a large number of extraocular 
locations such as visceral organs and skin (Ringvold 1972, 1973; Layden & Schaffer 1974; 
Harnisch 1977; Eagle et al. 1979; Streeten et al 1990, 1992; Sugino 1990; Schlötzer-
Schrehardt et al. 1991, 1992).These findings have led to the hypothesis that XFS/XFG is part 
of a generalized disorder, and suggested that this group of patients might have increased 
mortality rate.  
 
 
 
 
 8
Comorbidity 
Recently, increasing attention has been paid to the associations between POAG, XFG and 
XFS with some other diseases. Waldmann et al. (1996) found glaucoma, especially normal 
tension glaucoma, to be significantly associated with silent myocardial ischaemia. A high 
frequency of XFS has been observed in eyes with positive iris transluminance in patients who 
had been diagnosed with a transient ischaemic attack (Repo et al. 1995). Mitchell et al. (1997) 
found XFS to be significantly associated with a history of angina pectoris or hypertension or a 
combined history of angina pectoris, acute myocardial infarction or stroke. Studies have 
shown that patients with Alzheimer’s disease (AD) have a higher occurrence rate of glaucoma 
(Bayer et al. 2002; Tamura et al. 2006) and XFS (Hagadus et al. 1989; Linnér et al. 2001). 
Lower prevalence of diabetes mellitus in patients with XFS (Shingleton et al. 2003) and 
patients with XFG requiring surgery (Konstas et al. 1998) have also been demonstrated.  
 
Genetics 
Glaucoma is a neurodegenerative disease with a polygenic aetiology (Libby et al. 2005). 
McKinnon (2003) suggested the hypothesis of retinal ganglion cell death involving chronic 
amyloid-β neurotoxicity, mimicking AD at the molecular level, and questioned whether 
glaucoma may be an ocular form of AD. Inheritance of the ε4 allele of the gene encoding 
Apolipoprotein E (APOE), has been associated with AD (Corder et al. 1993). The APOE4 
allele may be a common risk factor for neurodegenerative diseases, and may be associated 
with increased loss of ganglion cells in the retina. Previous studies comparing APOE-
genotypes of glaucoma patients with controls have so far shown both positive (Vickers et al. 
2002; Jünemann et al. 2004; Mabuchi et al. 2005) and negative associations (Ressiniotis et al. 
2004; Lake et al. 2004).  
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APOE may promote the aggregation of amyloidogenic proteins into β-pleated sheet 
conformation that is typical of all amyloid deposits, and is directly involved in the amyloid 
deposition and fibril formation (Strittmatter et al. 1993; Castano et al. 1995). Therefore, it has 
been suggested that APOE-genotype may influence the risk for developing XFS, since the 
exfoliation material is an amyloid or at least an amyloid-like structure (Ringvold & Husby 
1973; Davanger & Pedersen 1975; Dark et al. 1977; Meretoja & Tarkkanen 1977; Streeten et 
al. 1986). Yilmaz and co-workers (2005) found the APOE2 allele to be significantly 
associated with the development of XFS, whereas the APOE3 allele was found to be 
protective.  
There is evidence for nicotinic cholinergic neurotransmission in the human retina (Hutchins & 
Hollyfield 1985), and recently nicotinic receptor subunit genes (CHRNA4 and CHRNB2) 
have been associated with AD (Kawamata & Shimohama 2002; Cook et al. 2004). APOE 
may influence the synthesis of acetylcholine (ACh) (Poirier 2000), the metabolism in 
cholinergic neurons (Dubelaar et al. 2004), the availability of ACh in the synapse (Cohen et 
al. 2003), and the affinity of cholinergic receptors (Klein & Yakel 2004), and therefore, it has 
been suggested that nicotinic receptor genes and APOE-genotype may have joint effects.  
APOE-genotypes and other eye diseases 
APOE-genotype may also have an impact on risk of development of other eye diseases among 
the elderly, such as cataract and age-related macular degeneration (AMD). Cataract and 
Alzheimer’s disease (AD) are both degenerative disorders where pathological protein 
aggregates plays an important role in the pathogenesis. It has been suggested that cataract and 
Alzheimer’s disease share the same aetiological mechanisms. Beta-amyloid (Abeta) deposited 
in the brain is a hallmark of Alzheimer’s disease (Benjamin et al. 1994), and Abeta is also 
found to be present in the lens of people with Alzheimer’s disease, causing equatorial, 
supranuclear cataract (Goldstein et al. 2003). Zetterberg and coworkers (2005) investigated 
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APOE alleles in 502 patients with senile cataract and a control group of 187 persons without 
finding any significant differences for any of the alleles. 
Several recent studies of APOE genotypes in patients with AMD compared to control groups 
found the APOE4-genotype to have a protective effect against AMD, while the APOE2-
genotype may increase the risk (Schmidt et al 2002; Baird et al. 2004). However, in a large 
population based cross sectional study with participants from the Atherosclerosis Risk in 
Communities study, no association was found (Wong et al. 2006).  
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5. Aims of the studies 
 
We wanted to compare the survival of patients hospitalized with either XFG or POAG, 
retrospectively, and to study the impacts of gender and acetazolamide use on survival.  
We also decided to look for differences between XFG and POAG patients in terms of acute 
cerebrovascular disease, heart disease and cancer diagnosed as the main cause of death, and to 
study if there was difference in comorbidity registered as acute cerebrovascular diseases, 
cardiovascular diseases, heart failure, cancer, senile dementia and cerebral atrophy/ chronic 
cerebrovascular ischaemia.  
We also wanted to study the impacts of acetazolamide on comorbidity. 
We wanted to evaluate the effects of APOE- and CHRNA4 (cholinergic receptor, nicotinic, 
alpha polypeptide 4)-genotypes on RNFL thickness at the optic disc, IOP, and on the risk of 
developing XFS.  
Furthermore, we wished to study if there is an association between APOE- genotype and 
cataract or AMD.  
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6. Material and methods 
 
The data of paper I and II includes patients with XFG or POAG finally hospitalized at the Eye 
Department, The National Hospital, Oslo, between 1961 and 1970. Patients with the 
additional diagnosis of diabetes mellitus were excluded. Of a total of 1320 patients registered, 
the central population register by the Norwegian Government Computer Centre gave 
information about lifetimes of 1147 individuals on a follow-up to 1 April 1994. Among them, 
20 women and 15 men were still alive. It was not possible to identify the remaining 173 
individuals separately. We found main death cause and additional diagnoses for all the dead 
individuals in the Norwegian Causes of Death Register. The study included 718 patients (438 
males/280 females) with a XFG and 429 patients (234 males/ 195 females) with a POAG.  
At the time of hospitalization the patients were routinely examined after dilatation of the 
pupil, and the diagnosis of XFG was made when finding pseudoexfoliation material on the 
anterior lens surface or dots at the pupillary border. 
We also categorized the patients according to the use of peroral acetazolamide. An 
acetazolamide user was defined as a patient who had used the medicine for at least 2 years 
and/or had left the hospital last time with a prescription for acetazolamide. There were 492 
patients defined as acetazolamide users, while 655 were defined as non-users. The data were 
analysed using a Cox proportional hazard model (Cox 1972). Possible non-linear effects of 
age and time covariates, possible interactions, and possible confounding effects, were checked 
and included in the model when present. 
 
The study population for paper II was identical to the one described above for paper I. We 
categorized the patients in subgroups according to diagnoses registered as main causes of death 
and comorbidity. Patients with acute cerebrovascular disease were registered with diagnoses 
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as cerebral thrombosis/embolism, cerebral haemorrhage or subarachnoidal haemorrhage. 
Diagnoses as acute myocardial infarction, angina pectoris and cardiovascular atherosclerosis 
were categorized as an ischaemic cardiovascular disease. Chronic cerebral diseases like 
cerebral atrophy and chronic cerebrovascular ischaemia were put in a unite group. Binary 
logistic regression was carried out with glaucoma type, acetazolamide use, gender, and age at 
death or last follow-up as possible explanatory variables. Separate analyses were carried out 
with the following endpoints: 1. Main death cause – cerebrovascular disease, cardiac disease 
and cancer. 2. Comorbidity – acute cerebrovascular disease, senile dementia, cerebral 
atrophy/ chronic cerebral ischaemia, senile dementia or cerebral atrophy/ chronic cerebral 
ischaemia, cancer, ischaemic cardiovascular disease and heart failure. 
Backwards likelihood ratio variable selection was performed, with p-entry = 0.05 and p-
remove = 0.10. Possible interactions were checked for variables in the models. Possible 
deviations from linear effect of age on odds ratio were checked by categorising age in 
quartiles. Effects were given as estimates and 95% confidence intervals.  
 
The study population for paper III and IV was a sample of 96 healthy middle-aged and older 
adults (50-75 years), participating in a study concerning cognitive ageing and genotyped for 
APOE and CHRNA4, who volunteered to enter the study. The study population was designed 
with 50 % APOE4-carriers and 50 % non-APOE4-carriers. The non-APOE4-carriers were 
frequency-matched for age and gender to the APOE4-carriers. 88 participants (25 males/ 63 
females, mean age 65.5 years) showed up for the examination. The carriers/ non-carriers ratio 
for the APOE-genotypes was; APOE2: 20/ 68, APOE3: 71/ 17 and APOE4: 43/ 45. The 
CHRNA4 genotypes had the following distribution; TT=29, TC=43 and CC=16. All 
participants underwent an eye examination including slit lamp examination, fundus 
photography as well as measurements of visual acuity, refraction, intraocular pressure (IOP), 
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and the retinal nerve fibre layer (NFL) thickness at the optic disc by optical coherence 
tomography. The average retinal NFL thickness at the optic disc (360 degrees) was measured, 
as well as the retinal NFL thickness in the superior, nasal, inferior and temporal quadrants. In 
case of possible glaucoma, another eye examination which included visual field testing by 
Humphrey autoperimeter and pachymetry was later performed. XFS was diagnosed during the 
slit-lamp examination after pupils were dilated by pharmacological agents. The physicians 
participating in the study were blinded for APOE- and CHRNA4-genotypes. 
 
The two-by-two tables were analyzed by the Fisher-Boschloo unconditional full multinomial 
test as recommended in small samples to avoid overly conservative results (Mehrotra et al 
2003). Two sample t-tests were used for comparing means of scale variables. All tests were 
two-sided, and p-values less than 0.05 were considered significant. 
 
The study population for paper IV was identical to the one described above for paper III. 
Fundus photography was also performed. The photos were analyzed and graded for macular 
pathology, such as drusen, hyperpigmentation, hypopigmentation, geographic atrophy, and 
neovascular AMD by the Reading Centre, Moorfields Eye Hospital, London. Macular 
thickness was measured by optical coherence tomography. Lens opacities were classified as 
nuclear, cortical, posterior subcapsular, or mixed forms of cataract. Intraocular lenses (IOL) 
due to previous cataract surgery were registered. Cataracts were classified only from a 
morphologic point of view, irrespective of visual acuity. The physicians were blinded for 
APOE-genotypes. The statistical methods for paper IV were identical with those used in 
paper III. 
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7. Summary of results 
 
Paper I 
The relative survival of the different subgroups of patients were analysed using the Cox 
proportional hazard model, based on survival time in years after diagnosis of glaucoma. We 
found no statistical significant differences of survival between XFG and POAG (p=0.85). 
Separate analyses for men and women confirmed these results. As expected, female gender as 
well as younger age at the time of diagnosis, was associated with longer survival. The use of 
acetazolamide had no statistical significant influence on survival until year of birth was 
included in the analyses. More recent birth date, or equivalently, more recent date of 
glaucoma diagnosis, was highly significantly associated with a reduction in survival. When 
year of birth was included in the analyses, the use of acetazolamide was associated with 
reduced survival (n=492, p=0.02).  
 
Paper II 
None of the explanatory variables were significantly associated with acute cerebrovascular 
disease as main cause of death. POAG versus XFG tended towards significance (p = 0.073, 
odds ratio 0.73, c.i. 0.52 to 1.03). Only age and gender were associated with cardiovascular 
disease as main cause of death; and only age was associated with death caused by cancer. 
The resulting logistic regression models for comorbidity analyses disclosed some interesting 
significant differences between the patients with XFG and POAG. Patients with a XFG more 
often had senile dementia (n=51, p=0.044) and senile dementia and/or cerebral atrophy/ 
chronic cerebral ischaemia (n=81, p=0.011) than patients with a POAG. Patients with XFG 
had a higher probability of having an acute cerebrovascular disease than patients with POAG 
(n=228, p=0.028). We also found that the use of acetazolamide was positively associated with 
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cerebral atrophy/ chronic cerebral ischaemia (p = 0.050) and with senile dementia and/or 
cerebral atrophy/ chronic cerebral ischaemia (p = 0.029). Increasing age turned out to be a 
significant explanatory variable in all the subgroups. Males were more likely than females to 
get an ischaemic cardiovascular disease (n=263, p=0.003), while females more often suffered 
from an acute cerebrovascular disease (n=228, p=0.052). In all the other subgroups gender 
was not a significant explanatory variable. 
 
Paper III 
No effect of the APOE- and CHRNA4-genotypes on the 360° RNFL thickness or on the four 
quadrants at the optic discs were revealed. The average RNFL thickness of the two eyes in the 
temporal quadrant showed a trend towards being thinner in the group of APOE4-carriers  that 
were also CHRNA4-TT-carriers (mean 37.4 μm) than in the non-APOE4/ CHRNA4-TT-
carriers (mean 40.8 μm) (p=0.055, CI: -0.76 to 6.80). However, the mean values of the RNFL 
thickness at the optic disc (360°) was non-significantly higher (104.6 μm) in the group of 
APOE4/ CHRNA4-TT-carriers than in the non-APOE4/ CHRNA4-TT-carriers (102.0 μm), as 
well as for the other three quadrants at the optic disc. There was no difference in refraction 
between any of the subgroups in the study. 
The average IOP of the two eyes of the participants had a mean value of 14.44 mmHg (range 
9-23 mmHg), while the maximum IOP for each person had a mean value of 15.15 mmHg 
(range 9-27 mmHg). We observed that the mean of the average IOP in the two eyes of the 
non-APOE2-carriers (14.82 mmHg) was significantly higher than in the eyes of the APOE2-
carriers (13.18 mmHg) (p=0.014, CI: 0.34 to 2.94). We found no other associations between 
the other APOE- and CHRNA4-alleles and IOP.  
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Exfoliation syndrome was present in one or both eyes in 15 participants. The presence of 
pseudoexfoliation was less likely in the CC-carriers of CHRNA4 than the TT- and TC-carriers 
(p=0.049). APOE-genotype did not show significant association with XFS. 
 
Paper IV 
There was no significant age difference between the APOE4 carriers (mean age 65.1 years) 
and the non-APOE4 carriers (mean age 65.9 years). Among the participants, 32 were 
diagnosed with cataract or had been through cataract surgery in one or both eyes, while 56 
showed no signs of cataract. We found that the APOE4-carriers were less likely to have 
cataract than the non-APOE4-carriers (p=0.039). The number of participants in the subgroups 
were; nuclear (3), cortical (15), posterior subcapsular cataract (16) and IOL (6). No significant 
associations were found between APOE-genotypes and subgroups of cataract. The 
participants diagnosed with cataract were older (mean 69.7 years) than those without (mean 
63.1 years) (p<0.001, CI: -9.30 to -3.82). 
Analyses of the fundus photographies of the macular region showed evidence of soft drusen 
in one or both eyes in 25 of 86 participants. However, only two persons had soft drusen with a 
size ≥ 125 μm. Hyperpigmentation was seen in 62 of 86 participants, while 33 out of 86 had 
areas of hypopigmentation. None of the participants showed evidence of geographic atrophy 
or neovascular AMD. No significant association between genotype and morphologic changes 
in the macular region of the retina was discovered. However, the APOE3-carriers had 
significantly higher average macular thickness (216.1μm) of the two eyes than the non-
APOE3-carriers (201.2μm) (p=0.012, CI: 3.42 to 26.38), and the APOE3-carriers also had a 
significantly better visual acuity (0.95) than the non-APOE3-carriers (0.87) (p=0.041, CI: 
0.003 to 0.153). 
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6. Discussion 
Ad I: Some previous studies have shown reduced survival rate for patients with open-angle 
glaucoma (Belloc 1963; Thorburn & Lindblom 1983; Egge & Zahl 1999; Hiller et al. 1999; 
Lee et al. 2003), while some other studies could not verify this (Bengtsson 1984; Borger et al. 
2003; Grødum et al. 2004; Knudtson et al. 2006; Lee et al. 2006). The studies based on older 
materials from the 1960s (Egge & Zahl 1999), 1970s (Hiller et al. 1999) and the 1980s 
(Thorburn & Lindblom 1983) show a tendency towards poorer survival among the glaucoma 
patients, while most of the studies based on more recent materials show no increased 
mortality among the glaucoma patients (Borger et al. 2003; Grødum et al. 2004; Knudtson et 
al. 2006; Lee et al. 2006). The diagnostic criteria and the glaucoma therapy have been through 
several changes during the last decades. Therefore, the study populations are presumably 
different in the older materials than in the more recent ones. The reasons why the studies 
based on older materials show a tendency towards reduced survival may be due to more 
severe glaucoma in the study groups, adverse effects of the therapy used at that time, or 
perhaps because longer follow-up increases the possibility of detecting a significant 
difference.  
Knudtson and coworkers (2006) demonstrated that visual impairment was associated with 
poorer survival and not explained by traditional risk factors for mortality. Accordingly, the 
divergence in study results could be related to the degree of visual impairment in the study 
sample. Whether the reduced survival rate for patients with open-angle glaucoma found in 
some of the studies is not caused by the glaucoma, but rather by the visual impairment, is yet 
not to be answered. However, Lee and coworkers (2006) have found an increased 
cardiovascular mortality in persons with previously diagnosed glaucoma. 
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It has been suggested that exfoliation syndrome or exfoliative glaucoma is part of a systemic 
process (Streeten et al. 1992) that may lead to increased mortality. To date no clear-cut 
association with a systemic disease has been shown. Recent studies showed no association 
between ocular XFS (Ringvold et al. 1997) or XFG (Grødum et al. 2004) and total, 
cardiovascular, and cerebrovascular mortality (Shrum et al. 2000). 
In the same study sample as we have studied, Egge & Zahl (1999) found an indication of 
increased mortality for glaucoma patients when the disease had lasted for some time. A 
comparative study of survival between patients with POAG and XFG (Paper I), have to our 
knowledge, not previously been performed. We found no statistical significant differences of 
survival between XFG and POAG. 
In the initial analyses, acetazolamide use had no significant impact on survival. When year of 
diagnosis was included in the analyses, acetazolamide use was significantly associated with 
reduced survival (p=0.02). If this was due to changes in cerebral blood flow when using 
acetazolamide that have been shown (Dahl et al. 1995; Shiogai et al. 2003), well known side 
effects such as metabolic acidosis and disturbances of the electrolyte balance, other unknown 
side-effects after long-term use of acetazolamide, or somehow related to that the glaucomas 
were more refractive to therapy, remains unknown. Literature studies and Medline search 
have not shown other reports of associations of acetazolamide use and reduced survival. 
There were no general guidelines at the National Hospital in the 1960s, whether the patients 
should undergo surgery or acetazolamide treatment when topical medication failed to control 
the disease. The patients were evaluated at an individual basis and several physicians were 
involved. A weakness of this study is that we were unable to find out whether the decision to 
treat with acetazolamide was based on considerations that patients were too frail to undergo 
surgery. 
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Surprisingly, more recent diagnosis of glaucoma or more recent birth date were highly 
significantly associated with increased mortality. The reason for this finding remains unclear. 
The distribution of ophthalmologists and the reference practice to the National Hospital did 
presumably not change much during the study period. The use of peroral acetazolamide seems 
to play a role, but this tendency could also be related to topical medical therapy for glaucoma, 
or maybe to drug-interaction of β-blockers, α2-agonists or miotic agents due to polypharmacy 
which became more common in elderly people in later years (Frishman et al. 2001). Lee and 
co-workers (2006) have suggested a higher cardiovascular mortality in patients using topical 
timolol. 
Ad II: The use of acetazolamide was positively associated with cerebral atrophy/chronic 
cerebral ischaemia (n=30, p = 0.050) and/or senile dementia (n=81, p = 0.029). However, it 
remains unclear whether acetazolamide use contributed to the development of senile 
dementia, or if this group of patients used more acetazolamide because they were more 
refractive to antiglaucomatous therapy (Bayer & Ferrari 2002) or not suited for surgery. 
Interestingly, in this study, we found that patients with a XFG were more likely to have senile 
dementia (n=51, p = 0.044), and/or chronic cerebrovascular ischaemia or cerebral atrophy 
(n=81, p=0.011). The reason why some persons with XFS develop XFG, and some not, 
remains unknown (Ritch et al. 2003). We have only studied patients with exfoliation 
syndrome who have developed glaucoma. Whether one could find the same associations for 
XFS that we have found for XFG, is at present an unanswered question. 
Konstas et al. (1998) found a lower prevalence of diabetes in patients with XFG requiring 
surgery than those with POAG. Shingleton et al. (2003) confirmed this finding by reporting a 
significantly greater prevalence of diabetes and hypertension in the non-exfoliation group than 
in the exfoliation group. We chose to exclude patients with diabetes mellitus, and this may 
have contributed to a small overrepresentation of XFG in our study.  
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A problem for retrospective studies like these is that some diagnoses may be missing, and the 
accuracy of the diagnoses may vary because some of the diseases have been diagnosed 
clinically without the use of modern paraclinically diagnostic techniques like ultrasound, 
MRI- and CT-scanning. Therefore, the percentages are probably lower than the true numbers 
of associated diagnoses and should not be read as absolute values. We presume, however, that 
if some co-diagnoses are missing or may not be accurate, these errors should be equally 
distributed in the subgroups we have studied. We are aware of the limitations of a 
retrospective study like this. Our results need to be followed up with further prospective 
studies before any definitive conclusion can be made of possible associations between XFG 
and chronic cerebral diseases and acute cerebrovascular disease. 
 
Ad III: In the studies investigating associations between APOE-genotypes and eye diseases 
such as glaucoma, AMD and cataract, our study design differed from the previous ones by 
examining a group of healthy volunteers where the selection was based on APOE genotype. 
By doing this, some of the bias associated with the case-control study design that had been 
used in the previous studies, were presumably avoided.  
Thinning of the RNFL at the optic disc may be the first sign of an optic neuropathy, and 
measurements of the RNFL thickness was chosen as a parameter to see if there were 
differences in the groups concerning loss of neural tissue. As far as we know, a study 
measuring RNFL thickness in subgroups of the APOE- and CHRNA4-genes has not been 
performed before. We found no significant difference of the RNFL thickness at the optic disc 
in the different genotype carriers of the APOE- and CHRNA4-genes, and thereby no evidence 
for increased loss of ganglion cells as an effect of these genes. The RNFL thickness in the 
temporal quadrant of the optic disc showed a trend towards being thinner in the group of 
APOE4-carriers that also were CHRNA4-TT-carriers (p=0.055). However, the mean values 
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of the RNFL thickness at the optic disc (360°) was non-significantly higher (104.6 μm) in the 
group of APOE4/ CHRNA4-TT-carriers than in the non-APOE4/ CHRNA4-TT-carriers 
(102.0 μm), as well as for the three other quadrants at the optic disc. Therefore, we cannot 
interpret this trend as a sign of increased neurodegeneration in the APOE4/ CHRNA4-TT 
subgroup. 
We found that the mean IOP in of the non-APOE2-carriers (14.8 mmHg) was significantly 
higher than the IOP of the APOE2-carriers (13.2 mmHg) (p=0.014), suggesting that the 
APOE2-genotype may have a lowering effect on the IOP. However, the retinal NFL thickness 
measurements showed no difference between these two groups, and both values are clearly 
within normal range, so the clinical relevance of this association remains uncertain. Our 
observation differs from a study of Jünemann and co-workers (2004) showing significantly 
higher IOP among the APOE2-carriers. However, the IOP-values in our study were not 
adjusted for corneal thickness. Mabuchi and co-workers (2005) have reported significantly 
lower IOP among the APOE4-carriers than among the non-APOE4-carriers. 
We studied the effect of genotype of APOE and of CHRNA4, a candidate gene for association 
with AD (Kawamata & Shimohama 2002; Cook et al. 2004), on the development of XFS. The 
presence of exfoliation was less likely in the CC-carriers of CHRNA4 than the TT- and TC-
carriers (p=0.049). However, Thorleifsson and co-workers (2007) recently identified two 
nonsynonymous single-nucleotide polymorphisms in exon 1 of the gene LOXL1. The study 
showed that the homozygous for the highest-risk haplotype had an increased risk of suffering 
from XFG of more than 100 times that of individuals carrying only low-risk haplotypes. The 
product of LOXL1 catalyzes the formation of elastin fibers. Therefore, it seems more likely 
that the exfoliation material is caused by disturbances in the elastin formation, rather than 
being an amyloid structure. 
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Ad IV: A study designed with healthy individuals genotyped for APOE to investigate a 
possible association between cataract and APOE polymorphism has, to our knowledge, not 
previously been performed. In our study, we found a weak negative correlation between 
APOE4 and cataract. This differs from the results of a case-control study where no such 
association was found (Zetterberg et al. 2004).  
Our study shows no significant association between morphologic changes in the macula and 
APOE genotype. The fact that population based cross sectional studies have failed to show an 
association between AMD risk and APOE genotype (Wong et al. 2006), in spite of animal 
models and studies on AMD patients demonstrating such a correlation, raises the issue 
whether the APOE genotype plays a role only if not another unknown factor is present at the 
same time. Further studies investigating APOE polymorphisms along with other variables in 
AMD patients are warranted to find possible factors contributing to the APOE4 genotype to 
give a protective effect in only certain populations. 
In our study, the APOE3-carriers had a significantly higher average macular thickness than 
the non-APOE3-carriers. Optical coherence tomography also demonstrated that the higher 
average macular thickness was not due to macular oedema in either of the participants. Hence, 
the higher macular thickness possibly explains why the APOE3-carriers also demonstrated a 
significantly better visual acuity than the non-APOE3-carriers. Consequently, APOE3 may 
act as a protective factor against loss of nerve fibres in the macular region.  
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7. Conclusions 
-There were no statistical significant differences in survival between the patients with XFG 
and POAG.  
-Female gender as well as younger age at the time of diagnosis were significantly associated 
with longer survival.  
-Patients with more recent birth date showed a shorter relative survival than the patients with 
an earlier birth date, and when this was included in the analyses, the use of acetazolamide was 
associated with reduced survival.  
-XFG and POAG showed no significant differences in rates of death caused by acute 
cerebrovascular diseases, cardiac diseases and cancer.  
-Chronic cerebral diseases as senile dementia, cerebral atrophy and chronic cerebral ischemia 
were more common in patients with XFG than with POAG, and in the group of acetazolamide 
users.  
-Patients with XFG had a higher probability of getting an acute cerebrovascular disease than 
patients with POAG.  
-No significant difference of the RNFL thickness at the optic disc in the different genotype 
carriers of the APOE- and CHRNA4-genes was found, and thereby no evidence for increased 
loss of ganglion cells in the retina as an effect of these genes.  
-The APOE2-carriers had significantly lower IOP than the non-APOE2-carriers.  
-The CC-carriers of the CHRNA4-gene in our study population were less likely to develop 
XFS.  
-There was no association between AMD and APOE polymorphism.  
-A weak negative association between APOE4 and cataract was disclosed.   
-APOE3-carriers demonstrated a significantly higher average macular thickness and a better 
visual acuity than the non-APOE3-carriers. 
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